Literature DB >> 9638442

Separate histogenesis of combined hepatocellular and cholangiocellular carcinoma in two patients.

Y Nagafuchi1, K Okamoto, M Shono, A Higure, H Todoroki, H Itoh, S Takeda, F Katumoto, S Toyoshima.   

Abstract

Double primary liver carcinomas, i.e. hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) are rare. Two patients in whom double primary liver carcinomas were surgically resected are described herein. Case 1: A 51-year-old Japanese man with chronic type B hepatitis underwent hepatectomy for primary HCC with intrahepatic metastasis. Case 2: A 67-year-old Japanese man with a history of rectal cancer and CCC underwent lateral hepatic segmentectomy for a suspected recurrence of intrahepatic CCC. Lack of direct contact between tumors, no evidence of histological transition and clearly different immunohistochemical staining for cytokeratin support a distinct histogenesis of the tumors in these two patients. The findings indicate that combined HCC and CCC can arise synchronously or metachronously as an intrahepatic double cancer.

Entities:  

Mesh:

Year:  1998        PMID: 9638442

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis.

Authors:  Takuya Watanabe; Jun Sakata; Takashi Ishikawa; Yoshio Shirai; Takeyasu Suda; Haruka Hirono; Katsuhiko Hasegawa; Kenji Soga; Koichi Shibasaki; Yukifumi Saito; Hajime Umezu
Journal:  World J Hepatol       Date:  2009-10-31

2.  Perihilar cholangiocarcinoma arising in hepatitis C virus-related liver cirrhosis with hepatocellular carcinoma.

Authors:  Takahiko Fujii; Yoh Zen; Yasuni Nakanuma
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

3.  Coincidental occurrence of hepatocellular carcinoma and cholangiocarcinoma (collision tumors) after liver transplantation: a case report.

Authors:  Waleed Al Hamoudi; Hatem Khalaf; Naglaa Allam; Mohammed Al Sebayel
Journal:  Hepat Mon       Date:  2012-10-28       Impact factor: 0.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.